<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38632311</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>17</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>3315</StartPage><MedlinePgn>3315</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3315</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-024-47720-8</ELocationID><Abstract><AbstractText>This study investigates the humoral and cellular immune responses and health-related quality of life measures in individuals with mild to moderate long COVID (LC) compared to age and gender matched recovered COVID-19 controls (MC) over 24 months. LC participants show elevated nucleocapsid IgG levels at 3 months, and higher neutralizing capacity up to 8 months post-infection. Increased spike-specific and nucleocapsid-specific CD4<sup>+</sup> T cells, PD-1, and TIM-3 expression on CD4<sup>+</sup> and CD8<sup>+</sup> T cells were observed at 3 and 8 months, but these differences do not persist at 24 months. Some LC participants had detectable IFN-&#x3b3; and IFN-&#x3b2;, that was attributed to reinfection and antigen re-exposure. Single-cell RNA sequencing at the 24 month timepoint shows similar immune cell proportions and reconstitution of na&#xef;ve T and B cell subsets in LC and MC. No significant differences in exhaustion scores or antigen-specific T cell clones are observed. These findings suggest resolution of immune activation in LC and return to comparable immune responses between LC and MC over time. Improvement in self-reported health-related quality of life at 24 months was also evident in the majority of LC (62%). PTX3, CRP levels and platelet count are associated with improvements in health-related quality of life.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Phetsouphanh</LastName><ForeName>Chansavath</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6617-5995</Identifier><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. cphetsouphanh@kirby.unsw.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacka</LastName><ForeName>Brendan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballouz</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Garvan Institute for Medical research, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Computer Science and Engineering, Faculty of Engineering, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Katherine J L</ForeName><Initials>KJL</Initials><Identifier Source="ORCID">0000-0002-9952-7069</Identifier><AffiliationInfo><Affiliation>Garvan Institute for Medical research, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Daniel B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manandhar</LastName><ForeName>Bikash</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klemm</LastName><ForeName>Vera</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Hyon-Xhi</ForeName><Initials>HX</Initials><Identifier Source="ORCID">0000-0003-1064-3934</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Victoria, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wheatley</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Victoria, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Anupriya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akerman</LastName><ForeName>Anouschka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milogiannakis</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starr</LastName><ForeName>Mitchell</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>NSW State Reference Laboratory for HIV, St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Phillip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>NSW State Reference Laboratory for HIV, St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turville</LastName><ForeName>Stuart G</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0003-1918-5343</Identifier><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kent</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-8539-4891</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Victoria, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrne</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Heart Lung Clinic, St. Vincent's Hospital Sydney and Faculty of Medicine and Health (UNSW), Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brew</LastName><ForeName>Bruce J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Peter Duncan Neurosciences Unit- St Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darley</LastName><ForeName>David R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-9721-101X</Identifier><AffiliationInfo><Affiliation>St. Vincent's Hospital, Darlinghurst, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dore</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Vincent's Hospital, Darlinghurst, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kelleher</LastName><ForeName>Anthony D</ForeName><Initials>AD</Initials><Identifier Source="ORCID">0000-0002-0009-3337</Identifier><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. akelleher@kirby.unsw.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Vincent's Hospital, Darlinghurst, NSW, Australia. akelleher@kirby.unsw.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Matthews</LastName><ForeName>Gail V</ForeName><Initials>GV</Initials><AffiliationInfo><Affiliation>The Kirby Institute, University of New South Wales, Sydney, NSW, Australia. gmatthews@kirby.unsw.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Vincent's Hospital, Darlinghurst, NSW, Australia. gmatthews@kirby.unsw.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>G.J.D. received grants from Gilead, Abbvie, Merck and Bristol-Myers Squibb, personal fees from Gilead, Abbvie and Merck, and nonfinancial support from Gilead, Abbvie and Merck, all outside the scope of the submitted work. B.J.B. received grants from St Vincent&#x2019;s Clinic during the conduct of the study; and consults for AbbVie, Janssen and Viiv, and grants from Biogen, all outside the scope of the submitted work. All other authors declare that there are no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>18</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>17</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38632311</ArticleId><ArticleId IdType="pmc">PMC11024141</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-47720-8</ArticleId><ArticleId IdType="pii">10.1038/s41467-024-47720-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;264. doi: 10.1038/s41586-021-03553-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM. Deleterious outcomes in long-hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. ACS Chem. Neurosci. 2020;11:4017&#x2013;4020. doi: 10.1021/acschemneuro.0c00725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00725</ArticleId><ArticleId IdType="pubmed">33275404</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM. Chronic COVID syndrome: need for an appropriate medical terminology for long-COVID and COVID long-haulers. J. Med. Virol. 2021;93:2555&#x2013;2556. doi: 10.1002/jmv.26624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26624</ArticleId><ArticleId IdType="pubmed">33095459</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes DL, et al. Post-COVID-19 symptom burden: what is Long-COVID and how should we manage it? Lung. 2021;199:113&#x2013;119. doi: 10.1007/s00408-021-00423-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-021-00423-z</ArticleId><ArticleId IdType="pmc">PMC7875681</ArticleId><ArticleId IdType="pubmed">33569660</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre, C.H. et al. Anosmia, ageusia, and other COVID-19-like symptoms in association with a positive SARS-CoV-2 test, across six national digital surveillance platforms: an observational study. Lancet. Digit. Health3, e577&#x2013;e586 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8297994</ArticleId><ArticleId IdType="pubmed">34305035</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, et al. Characteristics of adult outpatients and inpatients with COVID-19 - 11 Academic Medical Centers, United States, March-May 2020. MMWR Morb. Mortal. Wkly Rep. 2020;69:841&#x2013;846. doi: 10.15585/mmwr.mm6926e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6926e3</ArticleId><ArticleId IdType="pmc">PMC7332092</ArticleId><ArticleId IdType="pubmed">32614810</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23:210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263&#x2013;2264. doi: 10.1016/S0140-6736(22)00941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T, et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329:1934&#x2013;1946. doi: 10.1001/jama.2023.8823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Australian Institute of Health and Welfare. Long COVID in Australia &#x2013; a review of the literature, catalogue number PHE 318, (AIHW, Australian Government, 2022)</Citation></Reference><Reference><Citation>Global Burden of Disease Long, C.C. et al. Estimated Global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604&#x2013;1615. doi: 10.1001/jama.2022.18931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, et al. Immunological fingerprint in coronavirus disease-19 convalescents with and without post-COVID syndrome. Front. Med. 2023;10:1129288. doi: 10.3389/fmed.2023.1129288.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1129288</ArticleId><ArticleId IdType="pmc">PMC10165999</ArticleId><ArticleId IdType="pubmed">37168268</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa Cruz A, et al. Post-acute sequelae of COVID-19 is characterized by diminished peripheral CD8(+)beta7 integrin(+) T cells and anti-SARS-CoV-2 IgA response. Nat. Commun. 2023;14:1772. doi: 10.1038/s41467-023-37368-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37368-1</ArticleId><ArticleId IdType="pmc">PMC10061413</ArticleId><ArticleId IdType="pubmed">36997530</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreye J, Reincke SM, Pruss H. Do cross-reactive antibodies cause neuropathology in COVID-19? Nat. Rev. Immunol. 2020;20:645&#x2013;646. doi: 10.1038/s41577-020-00458-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00458-y</ArticleId><ArticleId IdType="pmc">PMC7537977</ArticleId><ArticleId IdType="pubmed">33024283</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat. Immunol. 2022;23:194&#x2013;202. doi: 10.1038/s41590-021-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, et al. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022;163:495&#x2013;506.e498. doi: 10.1053/j.gastro.2022.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Xu Y, Munier ML, Zaunders JJ, Kelleher AD. Single-cell profiling of lineage determining transcription factors in antigen-specific CD4(+) T cells reveals unexpected complexity in recall responses during immune reconstitution. Immunol. Cell Biol. 2017;95:640&#x2013;646. doi: 10.1038/icb.2017.28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2017.28</ArticleId><ArticleId IdType="pmc">PMC5550558</ArticleId><ArticleId IdType="pubmed">28485382</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, et al. Ratios of effector to central memory antigen-specific CD4(+) T cells vary with antigen exposure in HIV+ patients. Immunol. Cell Biol. 2014;92:384&#x2013;388. doi: 10.1038/icb.2013.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2013.101</ArticleId><ArticleId IdType="pubmed">24492798</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoo WH, et al. Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with mild/asymptomatic COVID-19. Clin. Immunol. 2023;246:109209. doi: 10.1016/j.clim.2022.109209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.109209</ArticleId><ArticleId IdType="pmc">PMC9758763</ArticleId><ArticleId IdType="pubmed">36539107</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MH, et al. Type I, II, and III interferon signatures correspond to coronavirus disease 2019 Severity. J. Infect. Dis. 2021;224:777&#x2013;782. doi: 10.1093/infdis/jiab288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab288</ArticleId><ArticleId IdType="pmc">PMC8244575</ArticleId><ArticleId IdType="pubmed">34467988</ArticleId></ArticleIdList></Reference><Reference><Citation>Utzschneider DT, et al. Early precursor T cells establish and propagate T cell exhaustion in chronic infection. Nat. Immunol. 2020;21:1256&#x2013;1266. doi: 10.1038/s41590-020-0760-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0760-z</ArticleId><ArticleId IdType="pubmed">32839610</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, J. et al. Distinguishing features of long COVID identified through immune profiling. Nature623, 139&#x2013;148 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, et al. High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells. Front Immunol. 2022;13:1032911. doi: 10.3389/fimmu.2022.1032911.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1032911</ArticleId><ArticleId IdType="pmc">PMC9762180</ArticleId><ArticleId IdType="pubmed">36544780</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin, K. et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat. Immunol.25, 218&#x2013;225 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10834368</ArticleId><ArticleId IdType="pubmed">38212464</ArticleId></ArticleIdList></Reference><Reference><Citation>Brkic Z, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren&#x2019;s syndrome and association with disease activity and BAFF gene expression. Ann. Rheum. Dis. 2013;72:728&#x2013;735. doi: 10.1136/annrheumdis-2012-201381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-201381</ArticleId><ArticleId IdType="pmc">PMC3618683</ArticleId><ArticleId IdType="pubmed">22736090</ArticleId></ArticleIdList></Reference><Reference><Citation>Wack A. Monocyte and dendritic cell defects in COVID-19. Nat. Cell Biol. 2021;23:445&#x2013;447. doi: 10.1038/s41556-021-00685-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-021-00685-y</ArticleId><ArticleId IdType="pubmed">33972732</ArticleId></ArticleIdList></Reference><Reference><Citation>Cysique LA, et al. The kynurenine pathway relates to post-acute COVID-19 objective cognitive impairment and PASC. Ann. Clin. Transl. Neurol. 2023;10:1338&#x2013;1352. doi: 10.1002/acn3.51825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51825</ArticleId><ArticleId IdType="pmc">PMC10424655</ArticleId><ArticleId IdType="pubmed">37318955</ArticleId></ArticleIdList></Reference><Reference><Citation>Staubli SM, et al. The role of CRP and Pentraxin 3 in the prediction of systemic inflammatory response syndrome and death in acute pancreatitis. Sci. Rep. 2019;9:18340. doi: 10.1038/s41598-019-54910-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-54910-8</ArticleId><ArticleId IdType="pmc">PMC6893028</ArticleId><ArticleId IdType="pubmed">31798002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanbay A, et al. Correlation between pentraxin-3 and endothelial dysfunction in obstructive sleep apnea syndrome. Ann. Thorac. Med. 2015;10:199&#x2013;203. doi: 10.4103/1817-1737.160840.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1817-1737.160840</ArticleId><ArticleId IdType="pmc">PMC4518351</ArticleId><ArticleId IdType="pubmed">26229563</ArticleId></ArticleIdList></Reference><Reference><Citation>Suliman ME, et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2008;3:976&#x2013;985. doi: 10.2215/CJN.03960907.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.03960907</ArticleId><ArticleId IdType="pmc">PMC2440283</ArticleId><ArticleId IdType="pubmed">18417746</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang Y, Roest M, de Laat B, de Groot PG, Huskens D. Interplay between platelets and coagulation. Blood Rev. 2021;46:100733. doi: 10.1016/j.blre.2020.100733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2020.100733</ArticleId><ArticleId IdType="pmc">PMC7354275</ArticleId><ArticleId IdType="pubmed">32682574</ArticleId></ArticleIdList></Reference><Reference><Citation>Seligman WH, et al. Which outcomes are most important to measure in patients with COVID-19 and how and when should these be measured? Development of an international standard set of outcomes measures for clinical use in patients with COVID-19: a report of the International Consortium for Health Outcomes Measurement (ICHOM) COVID-19 Working Group. BMJ Open. 2021;11:e051065. doi: 10.1136/bmjopen-2021-051065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-051065</ArticleId><ArticleId IdType="pmc">PMC8593274</ArticleId><ArticleId IdType="pubmed">34782342</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat. Med. 2022;28:2398&#x2013;2405. doi: 10.1038/s41591-022-02051-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02051-3</ArticleId><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin K, et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat. Immunol. 2024;25:218&#x2013;225. doi: 10.1038/s41590-023-01724-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01724-6</ArticleId><ArticleId IdType="pmc">PMC10834368</ArticleId><ArticleId IdType="pubmed">38212464</ArticleId></ArticleIdList></Reference><Reference><Citation>Darley DR, et al. Persistent symptoms up to four months after community and hospital-managed SARS-CoV-2 infection. Med J. Aust. 2021;214:279&#x2013;280. doi: 10.5694/mja2.50963.</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja2.50963</ArticleId><ArticleId IdType="pmc">PMC8014234</ArticleId><ArticleId IdType="pubmed">33657671</ArticleId></ArticleIdList></Reference><Reference><Citation>Darley, D.R. et al. Limited recovery from post-acute sequelae of SARS-CoV-2 at 8 months in a prospective cohort. ERJ Open Res.7, 00384 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8504133</ArticleId><ArticleId IdType="pubmed">34725634</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27:7&#x2013;22. doi: 10.1002/hec.3564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hec.3564</ArticleId><ArticleId IdType="pmc">PMC6680214</ArticleId><ArticleId IdType="pubmed">28833869</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaffrey N, Kaambwa B, Currow DC, Ratcliffe J. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms. Health Qual. Life Outcomes. 2016;14:133. doi: 10.1186/s12955-016-0537-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-016-0537-0</ArticleId><ArticleId IdType="pmc">PMC5028927</ArticleId><ArticleId IdType="pubmed">27644755</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal A, et al. Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. Nat. Microbiol. 2022;7:896&#x2013;908. doi: 10.1038/s41564-022-01135-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01135-7</ArticleId><ArticleId IdType="pmc">PMC9159941</ArticleId><ArticleId IdType="pubmed">35637329</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal A, et al. SARS-CoV-2 Omicron BA.5: evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. EBioMedicine. 2022;84:104270. doi: 10.1016/j.ebiom.2022.104270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104270</ArticleId><ArticleId IdType="pmc">PMC9482529</ArticleId><ArticleId IdType="pubmed">36130476</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>